Jacob Sands, M.D.

Jacob Sands, M.D.

National Spokesperson

Thoracic Medical Oncologist, Harvard Medical School, Dana-Farber Cancer Institute and Instructor of Medicine, Harvard Medical School

Areas of Expertise:
Lung cancer oncology, lung cancer screening, lung cancer stigma

Jacob Sands, M.D., is a thoracic medical oncologist at Dana-Farber Cancer Institute and an instructor of medicine at Harvard Medical School. He received his medical degree from the University of Cincinnati before completing residency in internal medicine and fellowship training in hematology/oncology at the University of California, Davis. Dr. Sands joined Dana-Farber Cancer Institute in 2017 where he sees individuals with lung cancer and leads the small cell lung cancer clinical research program.

Dr. Sands has an interest in lung cancer diagnostics and therapeutics with ongoing protocol development in non-small cell and small cell lung cancers. He is a member of the NCCN guidelines committees on small cell lung cancer and lung screening. Dr. Sands has given many invited talks on various aspects of lung cancer as well as talks with the public and patient advocacy organizations, such as a discussion on clinical trials for the Bonnie Addario Foundation “Living Room.” He serves on the GO2 Foundation (merged Bonnie Addario Lung Cancer Foundation and Lung Cancer Alliance) Scientific Leadership Board.

During the five years he was on staff at Lahey Hospital & Medical Center, Dr. Sands was a member of the steering committee that initiated a community benefit of lung screening, which developed into a lung screening program that many consider to be a model for other institutions. He has been an invited speaker on lung screening to many venues and serves as Treasurer of the Rescue Lung Rescue Life Society, an organization focused on increasing implementation of lung screening and pioneering early detection innovations.

Media interested in scheduling an interview with Dr. Sands may contact Media@Lung.org.

Page last updated: April 20, 2024

Lung Cancer Biomarker Testing
, | Nov 16, 2024